Sarcopenia
Welcome,         Profile    Billing    Logout  
 46 Companies   12 Products   12 Products   17 Mechanisms of Action   756 Trials   22406 News 


«12...6768697071727374757677...401402»
  • ||||||||||  Journal:  Aminopeptidase O Protein mediates the association between Lachnospiraceae and appendicular lean mass. (Pubmed Central) -  Feb 22, 2024   
    This supports the potential therapeutic modulation of gut microbiota for sarcopenia. Interventions such as drug treatments or microbiota transplantation, aimed at elevating Lachnospiraceae abundance and AOPEP inhibition, synergistically improve sarcopenia in the elderly, thereby enhancing the overall quality of life for older individuals.
  • ||||||||||  Biomarker, Journal:  Serum metabolome and gut microbiome alterations are associated with low handgrip strength in older adults. (Pubmed Central) -  Feb 22, 2024   
    The relative abundances of the genera Parabacteroides and Intestinibacter increased significantly in the low-HGS group and were negatively correlated with the serum levels of cinnamoylglycine. The identified metabolites whose levels were markedly altered, and intestinal flora associated with these metabolites suggest the potential metabolic underpinnings for HGS and provide a basis for the further identification of biomarkers of muscle strength decline in older adults.
  • ||||||||||  Enrollment open, HEOR:  Effects of Multicomponent Training in Older Adults (clinicaltrials.gov) -  Feb 21, 2024   
    P=N/A,  N=25, Recruiting, 
    As such, the presence of this factor may help predict tolerance of NAC. Not yet recruiting --> Recruiting
  • ||||||||||  Trial completion date, Trial primary completion date, Machine learning:  Update on the Detection of Frailty in Older Adults (clinicaltrials.gov) -  Feb 21, 2024   
    P=N/A,  N=500, Recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Feb 2025 --> Jun 2025 | Trial primary completion date: Dec 2024 --> Apr 2025
  • ||||||||||  Journal:  Medical and Cardiac Risk Stratification and Exercise Prescription in Persons With Cancer. (Pubmed Central) -  Feb 20, 2024   
    Special attention to risks of cardiac and pulmonary disease along with risks of sarcopenia, thrombocytopenia, anemia, neutropenia, fracture risk, neurotoxicity, lymphedema, and metastases should be made. This article will outline these specific risks and necessary modifications to the exercise prescription for cancer patients that can be used to enable safe participation in recommended exercise.
  • ||||||||||  Review, Journal:  Recent advances in skeletal muscle physiology. (Pubmed Central) -  Feb 20, 2024   
    Consideration of a name change, such as "systemic OA", could help to move away from the perception of a disease focused only on the joints. No abstract available
  • ||||||||||  Trial completion date, Trial primary completion date:  Sarcopenia and Nutritional Status in a Rehabilitation Setting (clinicaltrials.gov) -  Feb 20, 2024   
    P=N/A,  N=30, Recruiting, 
    These findings emphasize the importance of addressing osteosarcopenia in the elderly population to improve their overall well-being. Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
  • ||||||||||  Nocturnal Hypoxemia Is Associated With Sarcopenia in COPD Patients (San Diego Convention Center, Room 6B (Upper Level)) -  Feb 20, 2024 - Abstract #ATS2024ATS_7971;    
    We found that COPD patients have less pectoralis muscle mass than non-COPD patients, and that nocturnal hypoxemia was associated with an additional decrease in the pectoralis muscle of COPD patients. Our findings lay the foundation for future preclinical and clinical studies to determine the mechanisms of skeletal muscle loss due to nocturnal hypoxemia in COPD, and whether interventional studies targeting nocturnal hypoxemia can prevent or reverse this process.
  • ||||||||||  Trial completion date, Trial primary completion date:  Sarcopenia and Related Factors in Lipedema (clinicaltrials.gov) -  Feb 20, 2024   
    P=N/A,  N=102, Recruiting, 
    It Trial completion date: Dec 2023 --> May 2024 | Trial primary completion date: Dec 2023 --> Apr 2024
  • ||||||||||  Journal, Immune cell:  Ultrasound Pressure-Dependent Cytokine and Immune Cell Response Lost in Aged Muscle. (Pubmed Central) -  Feb 19, 2024   
    These findings suggest that prevention of sarcopenia during the pandemic required provision of opportunities for older adults to remain active and positive assessment of nutritional status and well-being. Therapeutic ultrasound induced a pressure-dependent inflammatory response that can augment or mitigate intrinsic muscle cytokine signaling and cell recruitment in adolescent or aged muscle, respectively.
  • ||||||||||  Journal:  Skeletal muscle ageing: lessons from teleosts. (Pubmed Central) -  Feb 17, 2024   
    Given the ease and affordability of husbandry, along with advances in genomics, genome editing technologies and imaging capabilities, teleost models are increasingly used for ageing and sarcopenia research. Here, we explain how teleost species such as zebrafish, African turquoise killifish and medaka recapitulate many of the classical hallmarks of sarcopenia, and discuss the various dietary, pharmacological and genetic approaches that have been used in teleosts to understand the mechanistic basis of sarcopenia.
  • ||||||||||  JQ-1 / Roche
    Journal:  The BET inhibitor JQ1 targets fat metabolism and counteracts obesity. (Pubmed Central) -  Feb 17, 2024   
    Here, we explain how teleost species such as zebrafish, African turquoise killifish and medaka recapitulate many of the classical hallmarks of sarcopenia, and discuss the various dietary, pharmacological and genetic approaches that have been used in teleosts to understand the mechanistic basis of sarcopenia. In conclusion, the current data highlight a potential benefit of JQ1 administration to counteract obesity, suggesting epigenetic modulation as a prospective target in the treatment of obesity and sarcopenic obesity, despite the underlying multiorgan molecular mechanism is still not completely elucidated.
  • ||||||||||  Journal:  Association Between Dietary Fiber Intake and Low Muscle Strength Among Korean Adults. (Pubmed Central) -  Feb 16, 2024   
    65 years, those in the lowest quartile of dietary fiber intake had a higher risk of low muscle strength than those in the highest quartile after adjustment of confounders (odds ratio 1.709; 95% confidence interval 1.130-2.585). These results suggest that adequate dietary fiber intake may reduce the risk of sarcopenia in older Korean women.
  • ||||||||||  Journal:  The Current Landscape of Pharmacotherapies for Sarcopenia. (Pubmed Central) -  Feb 16, 2024   
    A mas receptor agonist, BIO101, stands out as a recent promising pharmaceutical. In addition to the conventional strategies (i.e., nutritional support and physical exercise), therapeutics with multiple targets of action or combination of multiple therapeutics with different targets/modes of action appear to promise greater benefit for the prevention and treatment of sarcopenia.